| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 22.4% | +11.5% | $119M | $12.1M | 11.9M | +11.4% | RA Capital Management, L.P. | 04 Jun 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 7.8% | $40.5M | 3.94M | BVF PARTNERS L P/IL | 31 Dec 2024 | |||
| Canaan XI L.P. | 7.4% | $38.4M | 3.73M | Canaan XI L.P. | 31 Dec 2024 | |||
| Commodore Capital LP | 6.3% | +22% | $47.2M | $8.74M | 3.38M | +22.7% | Commodore Capital LP | 30 Sep 2025 |
| TCG Crossover GP I, LLC | 5.7% | $29.8M | 2.9M | TCG Crossover GP I, LLC | 27 Feb 2025 | |||
| JANUS HENDERSON GROUP PLC | 5.4% | +6% | $29.3M | $1.67M | 2.86M | +6.05% | JANUS HENDERSON GROUP PLC | 30 Jun 2025 |
| Vestal Point Capital, LP | 4.5% | -18% | $33.9M | -$6.36M | 2.43M | -15.8% | Vestal Point Capital, LP | 30 Sep 2025 |
| FMR LLC | 3.2% | $17.5M | 1.71M | FMR LLC | 31 Mar 2025 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Change | Price | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 55.6M | $778M | -$9.88M | $13.99 | 115 |
| 2025 Q2 | 56.6M | $542M | +$28.8M | $9.57 | 120 |
| 2025 Q1 | 53.6M | $500M | +$34.7M | $9.30 | 116 |
| 2024 Q4 | 48.6M | $676M | -$145M | $13.90 | 112 |
| 2024 Q3 | 47.1M | $1.11B | +$8.15M | $23.51 | 94 |
| 2024 Q2 | 46.8M | $749M | -$1.81M | $15.99 | 76 |
| 2024 Q1 | 46.9M | $768M | +$182M | $16.40 | 75 |
| 2023 Q4 | 35.8M | $495M | -$9.8M | $13.85 | 62 |
| 2023 Q3 | 36.5M | $502M | +$3.28M | $13.77 | 59 |
| 2023 Q2 | 36.2M | $617M | +$8.03M | $17.03 | 59 |
| 2023 Q1 | 35.7M | $573M | +$8.46M | $16.07 | 50 |
| 2022 Q4 | 35.2M | $268M | -$5.21M | $7.60 | 45 |
| 2022 Q3 | 35.7M | $314M | -$404K | $8.79 | 43 |
| 2022 Q2 | 35.7M | $256M | -$3.32M | $7.15 | 44 |
| 2022 Q1 | 36.1M | $387M | -$8.63M | $10.70 | 46 |
| 2021 Q4 | 35.2M | $494M | +$13.7M | $14.07 | 45 |
| 2021 Q3 | 26.1M | $457M | +$457M | $17.59 | 25 |